Table 4 Multivariable competing risk analysis of predictors of LTFU among TB/HIV-coinfected adults: 2017–2022.

From: A competing risk analysis of predictors of time to lost to follow-up among adults with TB/HIV coinfection in Bahir Dar

Covariates

Category

a1SDHR (95% CI)

p-value

a2SDHR (95% CI)

p-value

Age

0.98(0.95–1.01)

0.190

0.97( 0.94-1.00)

0.047*

Residence

Rural

3.39 (1.56–7.41)

0.002*

0.11(0.04–0.32)

0.001**

Urban

1

 

1

 

Sex

Female

1.77(0.80–3.89)

0.16

1.34(0.61–2.92)

0.47

Male

1

 

1

0.62

Marital status

Single

0.88(0.39–1.98)

0.75

1.14(0.42–3.11)

0.81

Married

1

 

1

 

Divorced

0.85(0.43–1.70)

0.65

2.81(1.01–7.82)

0.049*

Widowed

0.78(0.26–2.35)

0.66

5.92(2.17–16.15)

0.001**

Baseline BMI

< 18.5

1.49(0.53–4.20)

0.44

0.41(0.20–0.82)

0.012*

>=18.5

1

 

1

 

Baseline

Working

1

 

1

 

Functional

Ambulatory

1.41(0.65–3.05)

0.38

2.59(1.19–5.69)

0.017*

Status

Bedridden

1.32(0.55–3.17)

0.54

0.66(0.19–2.28)

0.52

Baseline WHO stage

Stage I

1

 

1

 

Stage II

1.05(0.24–4.52)

0.95

1.68(0.56–5.06)

0.36

Stage III

1.94(0.74–5.13)

0.18

1.56(0.70–3.48)

0.27

Stage IV

2.88(1.01–8.26)

0.049*

1.23(0.29–5.13)

0.78

Baseline Hgb level

< 11gm/dl

3.56(1.75–7.24)

0.001**

0.69(0.31–1.52)

0.35

>=11gm/dl

1

 

1

 

Adverse Drug event

No

1

 

1

 

Yes

0.68(0.21–2.17)

0.51

2.87(1.23–6.73)

0.015*

Opportunistic Infection

No

1

 

1

 

Yes

3.65(1.77–7.53)

0.001**

0.97(0.42–2.25)

0.95

ART Drug adherence

Good

1

 

0.61(0.18–2.07)

0.43

Fair

1.16(0.44–3.03)

0.77

1.93(0.66–5.61)

0.23

Poor

1.91(0.58–6.26)

0.28

5.72(2.36–13.84)

0.001*

Back to article page